<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467635</url>
  </required_header>
  <id_info>
    <org_study_id>2011PA002B</org_study_id>
    <nct_id>NCT01467635</nct_id>
  </id_info>
  <brief_title>EBUS-TBNA Versus EBUS-TBNB</brief_title>
  <official_title>Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Endobronchial Ultrasound Transbronchial Needle Biopsy (EBUS-TBNB) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chelsea and Westminster NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective diagnostic clinical study randomising patients undergoing endobronchial
      ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of enlarged mediastinal and
      hilar lymph nodes to have sampling using the usual EBUS-TBNA needle or a novel biopsy forceps
      (EBUS-TBNB).

      The study aims to establish whether the use of EBUS-TBNB can significantly increase the
      diagnostic yield over EBUS-TBNA, without an increase in complication rates.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Manufacturer did not develop and deliver the necessary biopsy forceps needles in time
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of lymph nodes sampled resulting in a definitive diagnosis (as defined in the protocol) in the two study arms.</measure>
    <time_frame>18 months</time_frame>
    <description>The definition of a &quot;definitive diagnosis&quot; is dependant on the diagnosis and is clarified below:
Carcinoma/lymphoma: The lymph node sample is adequate to make a diagnosis as well as provide immunohistochemistry information enabling subtyping of the tumour.
Sarcoidosis: The presence of well formed epithelioid non-caseating granulomas.
Mycobacterial infection: The presence of caseating granulomas, positive Ziehl Nielson staining for acid fast bacilli, or the tissue successfully cultures Mycobacterium.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in the complication rate between the two study arms</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mediastinal Lymphadenopathy</condition>
  <condition>Hilar Lymphadenopathy</condition>
  <condition>Carcinoma</condition>
  <condition>Lymphoma</condition>
  <condition>Sarcoidosis</condition>
  <condition>Mycobacterial Disease</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sampling using endobronchial ultrasound guided transbronchial needle aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endobronchial ultrasound guided lymph node sampling</intervention_name>
    <description>Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.</description>
    <arm_group_label>EBUS-TBNA</arm_group_label>
    <arm_group_label>EBUS-TBNB</arm_group_label>
    <other_name>Olympus EBUS-TBNA needle</other_name>
    <other_name>Olympus EBUS-TBNB biopsy forceps</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for EBUS-TBNA as part of clinical care

          -  Lymph nodes larger than 10mm in diameter

          -  Age &gt; 18 years

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Contraindications for needle or forceps biopsy (e.g. coagulopathy, anticoagulation,
             thrombocytopenia)

          -  Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaid Zoumot, MBBS, MRCP, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Royal Brompton Hospital NHS Foundation Trust, Chelsea and Westminster Hospital NHS Fundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pallav L Shah, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton Hospital NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thoraxklinik, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endobronchial ultrasound</keyword>
  <keyword>Transbronchial needle aspiration</keyword>
  <keyword>Transbronchial biopsy forceps</keyword>
  <keyword>Mediastinal lymphadenopathy</keyword>
  <keyword>Hilar lymphadenopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

